Cancer is a complex, heterogeneous disease, characterized by deregulation of signaling networks in the cell. Components of these deregulated networks are potential targets for therapy. However, it remains a major challenge to identify and select the right targets in individual patients and inhibition of these targets is often associated with short-lived responses.
Large-scale, genome-wide functional genomic screening allows for the unbiased identification of cancer-specific targets and the understanding of resistance, leading to the development of novel (combination) strategies for the treatment of cancer.
